噬血细胞性淋巴组织细胞增生症诊断和治疗的进展

吴聪; 郭涛

doi:10.13201/j.issn.1004-2806.2025.01.008

噬血细胞性淋巴组织细胞增生症诊断和治疗的进展

吴聪¹,
郭涛^1, ,

- 华中科技大学同济医学院附属协和医院血液科(武汉，430022)

详细信息

作者简介:
郭涛，华中科技大学同济医学院附属协和医院血液科主任医师、博士生导师。担任中国医师协会血液科医师分会委员，海峡两岸医药卫生交流协会血液病学专业委员会副主任委员，武汉血液学会主任委员，中国研究型医院协会生物治疗学组常务委员。《临床血液学杂志》《血栓与止血学》《国际输血及血液学杂志》及《临床急诊杂志》编委。湖北省噬血细胞综合征专家联盟理事长。

通讯作者: 郭涛，E-mail：guotao1968@163.com

中图分类号: R55

收稿日期: 2024-11-30

刊出日期: 2025-01-01

Progress in diagnosis and treatment of hemophagocytic lymphohistiocytosis

WU Cong¹,
GUO Tao^1, ,

- Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China

More Information

Corresponding author: GUO Tao, E-mail: guotao1968@163.com

Received Date: 30 November 2024

Publish Date: 01 January 2025

摘要

摘要: 噬血细胞性淋巴组织细胞增生症(hemophagocytic lymphohistiocytosis，HLH)，又称噬血细胞综合征(hemophagocytic syndrome，HPS)，是一种以免疫系统过度激活为特征的免疫失调综合征，由于T淋巴细胞、巨噬细胞和自然杀伤(NK)细胞无法控制的过度激活从而产生大量的细胞因子，进而引发多器官功能损伤、衰竭甚至死亡。目前，多部国内外指南或共识对HLH的诊断治疗和监测提出了原则性和针对性的指导意见。本文将结合目前国内外的指南、专家共识及现有的研究证据，对HLH诊断和治疗及其进展作一总结。
- 噬血细胞性淋巴组织细胞增生症 /
- 诊断 /
- 治疗 /
- 进展
Abstract: Hemophagocytic lymphohistiocytosis(HLH), also known as hemophagocytic syndrome(HPS), is an immunological disorder characterized by excessive immune activation.This condition arises from uncontrolled overactivation of T lymphocytes, macrophages, and natural killer(NK) cells, leading to a massive production of cytokines and subsequent multi-organ functional damage, failure, and even death. Currently, several domestic and international guidelines and consensus statements have provided principled and targeted guidance on the diagnosis, treatment, and monitoring of HLH.This article will summarize the progress in diagnosis and treatment of HLH by integrating current guidelines, expert consensus, and existing research evidence from both domestic and international sources.
- hemophagocytic lymphohistiocytosis /
- diagnosis /
- treatment /
- progress

HTML全文

参考文献(50)

[1]	Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy[J]. Nat Rev Rheumatol, 2016, 12(5): 259-268. doi: 10.1038/nrrheum.2015.179
[2]	Al-Samkari H, Berliner N. Hemophagocytic Lymphohistiocytosis[J]. Annu Rev Pathol, 2018, 13: 27-49. doi: 10.1146/annurev-pathol-020117-043625
[3]	Sandler RD, Tattersall RS, Schoemans H, et al. Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party(ADWP)and Transplant Complications Working Party(TCWP)[J]. Front Immunol, 2020, 11: 524. doi: 10.3389/fimmu.2020.00524
[4]	中国医师协会血液科医师分会, 中华医学会儿科学分会血液学组, 噬血细胞综合征中国专家联盟. 中国噬血细胞综合征诊断与治疗指南(2022年版)[J]. 中华医学杂志, 2022, 102(20): 1492-1499. doi: 10.3760/cma.j.cn112137-20220310-00488
[5]	Henter JI, Elinder G, Ost A. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society[J]. Semin Oncol, 1991, 18(1): 29-33.
[6]	Henter JI, Aricò M, Egeler RM, et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society[J]. Med Pediatr Oncol, 1997, 28(5): 342-347. doi: 10.1002/(SICI)1096-911X(199705)28:5<342::AID-MPO3>3.0.CO;2-H
[7]	Henter JI, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis[J]. Pediatr Blood Cancer, 2007, 48(2): 124-131. doi: 10.1002/pbc.21039
[8]	Janka GE. Hemophagocytic syndromes[J]. Blood Rev, 2007, 21(5): 245-253. doi: 10.1016/j.blre.2007.05.001
[9]	Trottestam H, Horne A, Aricò M, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol[J]. Blood, 2011, 118(17): 4577-4584. doi: 10.1182/blood-2011-06-356261
[10]	Bergsten E, Horne A, Aricó M, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study[J]. Blood, 2017, 130(25): 2728-2738. doi: 10.1182/blood-2017-06-788349
[11]	La Rosée P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults[J]. Blood, 2019, 133(23): 2465-2477. doi: 10.1182/blood.2018894618
[12]	吴小艳, 王琳, 陈鸿博. 噬血细胞综合征研究进展[J]. 中华实用儿科临床杂志, 2020, 35(15): 1125-1129. doi: 10.3760/cma.j.cn101070-20200715-01182
[13]	Lee JC, Logan AC. Diagnosis and Management of Adult Malignancy-Associated Hemophagocytic Lymphohistiocytosis[J]. Cancers(Basel), 2023, 15(6): 1839.
[14]	Rosado FG, Gopal P. Laboratory Features and Pathology of Cytokine Storm Syndromes[J]. Adv Exp Med Biol, 2024, 1448: 43-58.
[15]	Fatma A, Raida BS, Mourad C, et al. Performances of the H-score and the HLH-2004 score in the positive diagnosis of secondary hemophagocytic lymphohistiocytosis[J]. Curr Res Transl Med, 2024, 72(2): 103430. doi: 10.1016/j.retram.2023.103430
[16]	Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome[J]. Arthritis Rheumatol, 2014, 66(9): 2613-2620. doi: 10.1002/art.38690
[17]	Debaugnies F, Mahadeb B, Ferster A, et al. Performances of the H-Score for Diagnosis of Hemophagocytic Lymphohistiocytosis in Adult and Pediatric Patients[J]. Am J Clin Pathol, 2016, 145(6): 862-870. doi: 10.1093/ajcp/aqw076
[18]	王昭, 王晶石. 成人噬血细胞综合征诊断与治疗进展[J]. 临床血液学杂志, 2022, 35(1): 1-5. https://lcxy.whuhzzs.com/article/doi/10.13201/j.issn.1004-2806.2022.01.001
[19]	Zoref-Lorenz A, Murakami J, Hofstetter L, et al. An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis[J]. Blood, 2022, 139(7): 1098-1110. doi: 10.1182/blood.2021012764
[20]	La Rosée P. Detecting HLH in hematologic malignancies[J]. Blood, 2022, 139(7): 961-963. doi: 10.1182/blood.2021014675
[21]	王迁, 王旖旎, 王嫱, 等. 风湿性疾病相关噬血细胞综合征诊疗规范[J]. 中华内科杂志, 2023, 62(1): 23-30. doi: 10.3760/cma.j.cn112138-20221010-00749
[22]	Ravelli A, Minoia F, Davì S, et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative[J]. Arthritis Rheumatol, 2016, 68(3): 566-576. doi: 10.1002/art.39332
[23]	Rubin TS, Zhang K, Gifford C, et al. Perforin and CD107a testing is superior to NK cell function testing for screening patients for genetic HLH[J]. Blood, 2017, 129(22): 2993-2999. doi: 10.1182/blood-2016-12-753830
[24]	Xu XJ, Tang YM. Dilemmas in diagnosis and management of hemophagocytic lymphohistiocytosis in children[J]. World J Pediatr, 2020, 16(4): 333-340. doi: 10.1007/s12519-019-00299-3
[25]	Xu XJ, Luo ZB, Song H, et al. Simple Evaluation of Clinical Situation and Subtypes of Pediatric Hemophagocytic Lymphohistiocytosis by Cytokine Patterns[J]. Front Immunol, 2022, 13: 850443. doi: 10.3389/fimmu.2022.850443
[26]	Yuan S, Wang Y, Luo H, et al. Serum soluble VSIG4 as a surrogate marker for the diagnosis of lymphoma-associated hemophagocytic lymphohistiocytosis[J]. Br J Haematol, 2020, 189(1): 72-83. doi: 10.1111/bjh.16299
[27]	Sadaat M, Jang S. Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report[J]. J Immunother Cancer, 2018, 6(1): 49. doi: 10.1186/s40425-018-0365-3
[28]	Wang Y, Huang W, Hu L, et al. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis[J]. Blood, 2015, 126(19): 2186-2192. doi: 10.1182/blood-2015-05-644914
[29]	Wang J, Wang Y, Wu L, et al. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis[J]. J Hematol Oncol, 2016, 9(1): 84. doi: 10.1186/s13045-016-0317-7
[30]	Marsh RA. Salvage Therapy and Allogeneic Hematopoietic Cell Transplantation for the Severe Cytokine Storm Syndrome of Hemophagocytic Lymphohistiocytosis[J]. Adv Exp Med Biol, 2024, 1448: 611-622.
[31]	Horne A, Wickström R, Jordan MB, et al. How to Treat Involvement of the Central Nervous System in Hemophagocytic Lymphohistiocytosis?[J]. Curr Treat Options Neurol, 2017, 19(1): 3. doi: 10.1007/s11940-017-0439-4
[32]	Lounder DT, Khandelwal P, Chandra S, et al. Incidence and Outcomes of Central Nervous System Hemophagocytic Lymphohistiocytosis Relapse after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation[J]. Biol Blood Marrow Transplant, 2017, 23(5): 857-860. doi: 10.1016/j.bbmt.2017.02.011
[33]	Ehl S, Astigarraga I, von Bahr Greenwood T, et al. Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society[J]. J Allergy Clin Immunol Pract, 2018, 6(5): 1508-1517. doi: 10.1016/j.jaip.2018.05.031
[34]	Jesudas R, Nichols KE. Recent advances in the treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome[J]. Curr Opin Allergy Clin Immunol, 2022, 22(6): 364-370. doi: 10.1097/ACI.0000000000000865
[35]	Locatelli F, Jordan MB, Allen C, et al. Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis[J]. N Engl J Med, 2020, 382(19): 1811-1822. doi: 10.1056/NEJMoa1911326
[36]	Albeituni S, Verbist KC, Tedrick PE, et al. Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis[J]. Blood, 2019, 134(2): 147-159. doi: 10.1182/blood.2019000761
[37]	Keenan C, Nichols KE, Albeituni S. Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis[J]. Front Immunol, 2021, 12: 614704. doi: 10.3389/fimmu.2021.614704
[38]	Charlesworth JEG, Kavirayani A. Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis/macrophage activation syndrome: A systematic review[J]. Eur J Haematol, 2023, 111(3): 458-476. doi: 10.1111/ejh.14029
[39]	Mehta P, Cron RQ, Hartwell J, et al. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome[J]. Lancet Rheumatol, 2020, 2(6): e358-e367. doi: 10.1016/S2665-9913(20)30096-5
[40]	Ghuman A, Kumar K, Singh A. The use of intravenous anakinra in the treatment of secondary haemophagocytic lymphohistiocytosis(HLH): a case series[J]. Rheumatology, 2019, 58(Supplement_3): kez110.046. doi: 10.1093/rheumatology/kez110.046
[41]	Eloseily EM, Weiser P, Crayne CB, et al. Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis[J]. Arthritis Rheumatol, 2020, 72(2): 326-334. doi: 10.1002/art.41103
[42]	Dufranc E, Del Bello A, Belliere J, et al. IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome[J]. Crit Care, 2020, 24(1): 166. doi: 10.1186/s13054-020-02878-7
[43]	Kim JY, Kim M, Park JK, et al. Limited efficacy of tocilizumab in adult patients with secondary hemophagocytic lymphohistiocytosis: a retrospective cohort study[J]. Orphanet J Rare Dis, 2022, 17(1): 363. doi: 10.1186/s13023-022-02516-1
[44]	Geerlinks AV, Dvorak AM. A Case of XIAP Deficiency Successfully Managed with Tadekinig Alfa(rhIL-18BP)[J]. J Clin Immunol, 2022, 42(4): 901-903. doi: 10.1007/s10875-022-01236-2
[45]	Liu P, Pan X, Chen C, et al. Nivolumab treatment of relapsed/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults[J]. Blood, 2020, 135(11): 826-833. doi: 10.1182/blood.2019003886
[46]	Rajapakse P, Andanamala H. Hemophagocytic Lymphohistiocytosis Secondary to Immune Checkpoint Inhibitor Therapy[J]. World J Oncol, 2022, 13(2): 49-52. doi: 10.14740/wjon1464
[47]	Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab[J]. Pediatr Blood Cancer, 2013, 60(1): 101-109. doi: 10.1002/pbc.24188
[48]	Dettmer-Monaco V, Weißert K, Ammann S, et al. Gene editing of hematopoietic stem cells restores T-cell response in familial hemophagocytic lymphohistiocytosis[J]. J Allergy Clin Immunol, 2024, 153(1): 243-255. e14. doi: 10.1016/j.jaci.2023.08.003
[49]	Weißert K, Ammann S, Kögl T, et al. Adoptive T cell therapy cures mice from active hemophagocytic lymphohistiocytosis(HLH)[J]. EMBO Mol Med, 2022, 14(12): e16085. doi: 10.15252/emmm.202216085
[50]	Li X, Wirtz T, Weber T, et al. Precise CRISPR-Cas9 gene repair in autologous memory T cells to treat familial hemophagocytic lymphohistiocytosis[J]. Sci Immunol, 2024, 9(92): eadi0042. doi: 10.1126/sciimmunol.adi0042